Rigel Pharmaceuticals has been granted a patent for imidazole compounds that can inhibit a cellular TAM receptor and be used to treat diseases involving the TAM receptor family. The patent claims a compound with a specific structure formula (I). GlobalData’s report on Rigel Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Rigel Pharmaceuticals, cancer treatment biomarkers was a key innovation area identified from patents. Rigel Pharmaceuticals's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11672791B2) discloses a compound with a specific structure formula (I). The compound is further described in claim 2, where it has the structure of formula (Ie). In claim 3, it is mentioned that the compound has RY1 as —OR. Moving on to claim 4, it states that X in the compound can be hydrogen, Cak(C0-C6alkyl), or Hca(C0-C6alkyl), with each Cak, Hca, and alkyl group optionally substituted by one to three —RX1 groups. Claim 5 narrows down the possibilities for X to hydrogen or Hca(C0-C6alkyl), with each Hca and alkyl group optionally substituted by one to three —RX1 groups.
Claims 6 and 7 describe the compound with the structure of formula (If) and formula (II), respectively. Claim 8 specifies that in formula (II), ring A has a certain configuration. Claim 9 reiterates the presence of ring A in the compound described in claim 1. Moving on to claim 10 and 11, they mention that the compound of formula (II) can have a value of "a" as 0 or 1, respectively.
In claim 12, it is stated that Z in the compound can be Cak(C0-C6alkyl) substituted by one to three —RZ1 groups, where each —R2 can be independently halogen, cyano, C1-C6haloalkyl, —C1-C6alkoxy, oxo, —OR, —SR, —NR2, —C(O)R, —C(O)OR, —C(O)NR2, —S(O)2NR2, —S(O)2R, —OC(O)R, —N(R)C(O)R, —OC(O)OR, —OC(O)NR2, —N(R)C(O)OR, —N(R)C(O)NR2, —N(R)S(O)2R, —OP(O)(OR)2, or —CH2—OP(O)(OR). Alternatively, Z can be Cak optionally substituted by one to three —RZ1 groups, where each —R2 is independently halogen, C1-C6alkyl, or C1-C6haloalkyl.
Claim 13 further specifies the possibilities for Z, where it can be Cak substituted by one to three —RZ1 groups, with each —R2 having the same substituents as mentioned in claim 12. Claim 14 narrows down the options for Z in claim 13 to Cak(C1-C6alkyl) substituted by one to three —RZ1 groups, where each —RZ1 is independently halogen or C1-C6haloalkyl.
Moving on to claims 15 and 16, they describe the compound with the structure of formula (III) and formula (IV), respectively.
The patent also discloses methods of inhibiting a cellular TAM receptor (claim 17) and treating a disease or condition involving the TAM receptor family, specifically hematological neoplasms like acute myeloid leukemia (AML) (claim 18). In claim 19, it is mentioned that the hematological neoplasm can be AML. Finally, claim 20 specifies that the compound can be administered to a human subject for inhibiting the TAM receptor.
To know more about GlobalData’s detailed insights on Rigel Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
